Literature DB >> 24900330

The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design.

Haizhen Zhong1, Melissa A Wees1, Theresa D Faure1, Carol Carrillo2, Jack Arbiser2, J Phillip Bowen3.   

Abstract

The influence of ionization states of hydroxamates and retrohydroxamates and the presence of zinc ions in the active site were investigated using the wild-type and E402Q mutant of MMP-9. The deprotonated hydroxamates showed a significantly enhanced enrichment factor in the presence of zinc ions. A pharmacophore model was developed based on the deprotonated compounds and was used to identify four structurally diverse compounds with antiproliferative activities.

Entities:  

Keywords:  Protonation state; and zinc binding group; chalcone; curcumin

Year:  2011        PMID： 24900330      PMCID： PMC4018105          DOI： 10.1021/ml200031m

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  23 in total

1.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors.

Authors:  S P Gupta; S Kumaran
Journal:  Bioorg Med Chem       Date:  2005-09-15       Impact factor: 3.641

3.  Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

Authors:  Carol K Wada; James H Holms; Michael L Curtin; Yujia Dai; Alan S Florjancic; Robert B Garland; Yan Guo; H Robin Heyman; Jamie R Stacey; Douglas H Steinman; Daniel H Albert; Jennifer J Bouska; Ildiko N Elmore; Carole L Goodfellow; Patrick A Marcotte; Paul Tapang; Douglas W Morgan; Michael R Michaelides; Steven K Davidsen
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

4.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.

Authors:  J L Arbiser; M A Moses; C A Fernandez; N Ghiso; Y Cao; N Klauber; D Frank; M Brownlee; E Flynn; S Parangi; H R Byers; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

5.  Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B.

Authors:  R Mohan; J Sivak; P Ashton; L A Russo; B Q Pham; N Kasahara; M B Raizman; M E Fini
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

6.  A quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.

Authors:  S P Gupta; Dalip Kumar; S Kumaran
Journal:  Bioorg Med Chem       Date:  2003-05-01       Impact factor: 3.641

Review 7.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

8.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

9.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.

Authors:  Veronica C Ardi; Tatyana A Kupriyanova; Elena I Deryugina; James P Quigley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

10.  Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity.

Authors:  Anna Tochowicz; Klaus Maskos; Robert Huber; Ruth Oltenfreiter; Vincent Dive; Athanasios Yiotakis; Matteo Zanda; Tayebeh Pourmotabbed; Wolfram Bode; Peter Goettig
Journal:  J Mol Biol       Date:  2007-05-31       Impact factor: 5.469
View more
  3 in total

1.  Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4.

Authors:  Qian Xu; Amol A Kulkarni; Ayyiliath M Sajith; Dilbi Hussein; David Brown; Osman F Güner; M Damoder Reddy; E Blake Watkins; Bernard Lassègue; Kathy K Griendling; J Phillip Bowen
Journal:  Bioorg Med Chem       Date:  2017-12-17       Impact factor: 3.641

2.  Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.

Authors:  Qi Gao; Yijun Wang; Jiaying Hou; Qizheng Yao; Ji Zhang
Journal:  J Comput Aided Mol Des       Date:  2017-06-16       Impact factor: 3.686

3.  The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.

Authors:  Ingebrigt Sylte; Rangita Dawadi; Nabin Malla; Susannah von Hofsten; Tra-Mi Nguyen; Ann Iren Solli; Eli Berg; Olayiwola A Adekoya; Gunbjørg Svineng; Jan-Olof Winberg
Journal:  PLoS One       Date:  2018-08-03       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.